Myeloproliferative Neoplasms MPN


Year In Review 2016 MPN (February 27, 2017)

Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening... Continue Reading

When Good Cells Go Bad (February 20, 2017)

By Kari Bohlke, ScD Cancer. The word has taken on a meaning that extends beyond the medical definition. Cancer is deadly; it is dangerous; it means bad news. But when we hear the words, “You have cancer,”... Continue Reading

CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib (January 6, 2017)

CTI BioPharma Corp. announced that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted under the Investigational New Drug... Continue Reading

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis (December 20, 2016)

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients... Continue Reading

Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia (December 16, 2016)

The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were recently presented at the 2016 annual meeting of the American... Continue Reading

Myeloproliferative Neoplasms (December 15, 2016)

Cancer Connect MPN Community Cancer Connect MPNCommunity provides current, comprehensive, reliable information on PV, ET, and MF and a community where Multiple Myeloma cancer patients can exchange information... Continue Reading

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published... Continue Reading

Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life (October 10, 2016)

According to results from the myeloproliferative neoplasms (MPN) Landmark survey, MPN’s negatively affect the quality of life and overall health of patients even a year before their diagnosis. Myeloproliferative... Continue Reading

About PCROWD, Dana-Farber’s tissue-banking study for patients with Myeloproliferative Neoplasms, Smoldering Multiple Myeloma, Smoldering Waldenstrom’s Macroglobulemia, and Early Myelodysplastic Syndromes (June 27, 2016)

PCROWD (“Precursor CROWDsourcing”) – a tissue banking and clinical information study and repository – is an indispensable component of the blood cancer research pipeline. The main objective... Continue Reading

Jakafi Superior to Standard Treatment in Polycythemia Vera (June 21, 2016)

Treatment with Jakafi® (ruxolitinib) was superior to best available treatment among patients with inadequately controlled polycythemia vera (PV). These results were recently presented at the 21st Congress... Continue Reading

Jakafi Significantly Improves Long-Term Outcomes in Myelofibrosis (June 7, 2016)

The agent Jakafi® (ruxolitinib) has demonstrated significant improvements in long-term outcomes for patients diagnosed with myelofibrosis. These results were recently presented at the 2016 annual meeting... Continue Reading

Polycythemia Vera Today (May 19, 2016)

Polycythemia vera (PV) is a type of blood cancer known as a myeloproliferative neoplasm. It involves the abnormal development and function of bone marrow cells that produce blood cells, and leads to the... Continue Reading

Pacritinib Development in Myelofibrosis Placed on Clinical Hold by the FDA (April 27, 2016)

The investigative agent, pacritinib, being evaluated for treatment of myelofibrosis has been placed on full clinical hold by the United States Food and Drug Administration (FDA). All trials including treatment... Continue Reading

MPN Research Foundation Launches CancerConnect Social Media Platform (March 2, 2016)

Austin TX/Sun Valley ID– With the launch of the CancerConnect online community, the MPN Research Foundation (MPNRF) now offers a specialized social network for individuals affected by myeloproliferative... Continue Reading

Year in Review: Myeloproliferative Neoplasms (February 10, 2016)

Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening... Continue Reading

All Symptomatic Polycythemia Vera Patients May Benefit From Treatment with a JAK2 Inhibitor (December 29, 2015)

Patients with polycythemia vera (PV) experience significant symptoms characterized by fatigue, itching, night sweats, bone pain, fever, and undesired weight loss that contribute to a poor quality of life... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

MPN Clinical Trial Highlights (August 5, 2015)

Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. Future progress in the treatment of myeloproliferative neoplasms (MPNs) will result from the continued... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS